Harmony Biosciences (HRMY) to Release Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is projected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Harmony Biosciences to post earnings of $0.74 per share and revenue of $201.25 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Harmony Biosciences Trading Down 0.9 %

Shares of HRMY opened at $34.56 on Monday. The company has a market capitalization of $1.97 billion, a P/E ratio of 16.38, a P/E/G ratio of 0.47 and a beta of 0.80. Harmony Biosciences has a one year low of $28.14 and a one year high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock has a 50-day moving average price of $36.57 and a 200 day moving average price of $35.81.

Insider Transactions at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey Dierks sold 1,123 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HRMY shares. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective on the stock. Cantor Fitzgerald upped their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC cut their price objective on Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Mizuho cut their price objective on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Wednesday, February 19th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $53.67.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.